Filtros de búsqueda

Lista de obras de Tomás Pascual

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

artículo científico publicado en 2019

A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Typ

artículo científico publicado en 2019

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

artículo científico publicado en 2017

A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

scientific article published on 22 September 2020

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

artículo científico publicado en 2018

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases

artículo científico publicado en 2016

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.

artículo científico publicado en 2018

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

scientific article published on 01 June 2019

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

artículo científico publicado en 2017

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

scientific article published on 14 July 2020

Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2

scientific article published on 24 January 2019

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

scientific article published on 13 May 2020

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

artículo científico publicado en 2020

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

artículo científico publicado en 2020

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

artículo científico publicado en 2017

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

artículo científico publicado en 2021

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

artículo científico publicado en 2019

Intrinsic molecular subtypes of HER2+ breast cancer.

artículo científico publicado en 2017

Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?

artículo científico publicado en 2016

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

artículo científico publicado en 2017

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

artículo científico publicado en 2019

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

artículo científico publicado en 2019

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

scientific article published on 16 September 2020

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

scientific article published on 20 January 2020

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

artículo científico publicado en 2017

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

scientific article published on 11 December 2019

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer

scientific article published on 07 July 2020

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

artículo científico publicado en 2019

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

artículo científico

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda